http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2536289-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_458c78360f430826431e460e2ef4e9fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47f8a39dd322a6b650f2e7449853f402
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-525
filingDate 2013-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b27dbd3cb1877a6bc4464963a8568e49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_757d698ffb92bbe4e0953b28038ec895
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e74dd3931c32cce5cd6a1823069a011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73615ca600be680fa7701bca24c8098a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_410d055249ba9ffc1131508cdf625bce
publicationDate 2014-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2536289-C1
titleOfInvention Method of treating degenerative-dystrophic diseases of locomotor apparatus
abstract FIELD: medicine. n SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days. n EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects. n 3 tbl, 2 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2725688-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2611767-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2618928-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2640001-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-039819-B1
priorityDate 2013-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2433844-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46174089
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415712569
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5877
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1117
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535430
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447732273
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121837
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448307317
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526588
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124978
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5744
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457588632
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6741
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412584818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3032771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581151
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24766
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501353

Total number of triples: 54.